CN1553814B - 用于治疗动脉硬化的药物组合物 - Google Patents

用于治疗动脉硬化的药物组合物 Download PDF

Info

Publication number
CN1553814B
CN1553814B CN028095529A CN02809552A CN1553814B CN 1553814 B CN1553814 B CN 1553814B CN 028095529 A CN028095529 A CN 028095529A CN 02809552 A CN02809552 A CN 02809552A CN 1553814 B CN1553814 B CN 1553814B
Authority
CN
China
Prior art keywords
spla
type spla
ldl
type
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN028095529A
Other languages
English (en)
Chinese (zh)
Other versions
CN1553814A (zh
Inventor
杂贺昭彦
小野隆
山田胜利
花崎浩二
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of CN1553814A publication Critical patent/CN1553814A/zh
Application granted granted Critical
Publication of CN1553814B publication Critical patent/CN1553814B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN028095529A 2001-03-19 2002-03-19 用于治疗动脉硬化的药物组合物 Expired - Fee Related CN1553814B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2001078569 2001-03-19
JP78569/2001 2001-03-19
JP401289/2001 2001-12-28
JP2001401289 2001-12-28
PCT/JP2002/002585 WO2002074342A1 (en) 2001-03-19 2002-03-19 Remedies for arteriosclerosis

Publications (2)

Publication Number Publication Date
CN1553814A CN1553814A (zh) 2004-12-08
CN1553814B true CN1553814B (zh) 2010-05-26

Family

ID=26611547

Family Applications (1)

Application Number Title Priority Date Filing Date
CN028095529A Expired - Fee Related CN1553814B (zh) 2001-03-19 2002-03-19 用于治疗动脉硬化的药物组合物

Country Status (14)

Country Link
US (1) US20040248898A1 (enExample)
EP (2) EP1378246B1 (enExample)
JP (1) JP4499361B2 (enExample)
KR (1) KR100908968B1 (enExample)
CN (1) CN1553814B (enExample)
AT (1) ATE428425T1 (enExample)
BR (1) BR0208275A (enExample)
CA (1) CA2441110C (enExample)
DE (1) DE60231969D1 (enExample)
ES (1) ES2324766T3 (enExample)
MX (1) MXPA03008440A (enExample)
PT (1) PT1378246E (enExample)
TW (1) TWI314457B (enExample)
WO (1) WO2002074342A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2002000621A1 (ja) * 2000-06-29 2004-04-22 塩野義製薬株式会社 Ｘ型ｓＰＬＡ２阻害作用を有する化合物
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
NZ554491A (en) 2004-10-12 2009-07-31 Decode Genetics Ehf Sulfonamide peri-substituted bicyclics for occlusive artery disease
PT1852433E (pt) 2004-10-29 2012-02-08 Zeria Pharm Co Ltd Derivados de carbazole, seus solvatos ou seus sais farmaceuticamente aceitáveis
MX2008005666A (es) 2005-11-03 2009-03-02 Ilypsa Inc Compuestos multivalentes de indol y uso de los mismos como inhibidores de fosfolipasa-a2.
WO2007056275A2 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Indole compounds having c4-amide substituents and use thereof as phospholipase-a2 inhibitors
WO2007137042A2 (en) 2006-05-16 2007-11-29 Decode Genetics, Ehf. Process for preparing 7- (acryl0yl) -ind0les
US8048880B2 (en) * 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
CN101742907A (zh) * 2007-05-03 2010-06-16 安塞拉制药有限公司 采用分泌型磷脂酶a2（spla2）抑制剂和spla2抑制剂组合疗法治疗心血管疾病和血脂异常
US20090062369A1 (en) * 2007-08-31 2009-03-05 Joaquim Trias Use of secretory phospholipase a2 (spla2) inhibitors to decrease spla2 levels
WO2010038104A1 (en) * 2008-10-03 2010-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event.
KR101357438B1 (ko) 2009-04-29 2014-02-06 아마린 코포레이션 피엘씨 Ｅｐａ 및 심혈관 제제를 포함하는 제약 조성물 및 그의 사용 방법
KR101037404B1 (ko) * 2010-12-07 2011-05-30 박철형 가변설치가 가능한 압출본체에 의한 천장용 엘이디 조명등

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654326A (en) * 1994-04-01 1997-08-05 Eli Lilly And Company 1H-indole-3-glyoxylamide SPLA2 inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
IL109309A (en) 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
EP0658205B1 (en) * 1993-06-25 2000-03-15 Smithkline Beecham Plc Lipoprotein associated phospholipase a2, inhibitors thereof and use of the same in diagnosis and therapy
US5498608A (en) * 1994-01-07 1996-03-12 Salix Pharmaceuticals Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
MX9700511A (es) 1994-07-21 1997-04-30 Lilly Co Eli Inhibidores de spla2 de indolizina.
US5641800A (en) * 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
US6214876B1 (en) * 1994-07-21 2001-04-10 Eli Lilly And Company Indene-1-acetamide sPLA2 inhibitors
US6160175A (en) 1995-12-13 2000-12-12 Eli Lilly And Company Naphthyl acetamides as sPLA2 inhibitors
EP0779273B1 (en) 1995-12-13 2002-03-20 Eli Lilly And Company Naphthyl glyoxamides as sPLA2 inhibitors
TR199900956T2 (xx) * 1996-10-30 1999-07-21 Eli Lilly And Company S�bstit�e edilmi� trisiklik bile�imler.
US6353128B1 (en) 1996-12-03 2002-03-05 Eli Lilly And Company Phenyl acetamides as sPLA2 inhibitors
US5916922A (en) 1996-12-03 1999-06-29 Eli Lilly And Company Phenyl glyoxamides as SPLA2 inhibitors
ID18983A (id) 1996-12-04 1998-05-28 Lilly Co Eli Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
US5919774A (en) 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
WO1999051605A1 (en) 1998-03-31 1999-10-14 Shionogi & Co., Ltd. PYRROLO[1,2-a]PYRAZINE sPLA2 INHIBITOR
BR9911048A (pt) * 1998-05-21 2001-02-06 Shionogi & Co Inibidor de spla2 de pirrolo[1,2-b]piridazina
CA2346334A1 (en) * 1998-10-14 2000-04-20 Shionogi & Co., Ltd. Composition for treating or preventing ischemia reperfusion injury
US6756376B1 (en) * 1999-11-15 2004-06-29 Shionogi & Co., Ltd. Tricyclic azaindolizine derivatives having an sPLA2-inhibitory activities
JPWO2002000621A1 (ja) * 2000-06-29 2004-04-22 塩野義製薬株式会社 Ｘ型ｓＰＬＡ２阻害作用を有する化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654326A (en) * 1994-04-01 1997-08-05 Eli Lilly And Company 1H-indole-3-glyoxylamide SPLA2 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Yokata等.Suppression of murine endotoxic shock by sPLA2 inhibitor,indoxam, through group IIA sPLA2-independent mechanisms.Biochimica et Biophysica Acta 1438.1999,第216页. *

Also Published As

Publication number Publication date
DE60231969D1 (de) 2009-05-28
EP1378246A4 (en) 2004-07-07
WO2002074342A1 (en) 2002-09-26
JPWO2002074342A1 (ja) 2004-07-08
EP2044958A2 (en) 2009-04-08
CA2441110A1 (en) 2002-09-26
JP4499361B2 (ja) 2010-07-07
CN1553814A (zh) 2004-12-08
ATE428425T1 (de) 2009-05-15
TWI314457B (enExample) 2009-09-11
KR20030085026A (ko) 2003-11-01
BR0208275A (pt) 2004-04-13
EP1378246B1 (en) 2009-04-15
KR100908968B1 (ko) 2009-07-22
CA2441110C (en) 2010-10-12
MXPA03008440A (es) 2004-01-29
EP1378246A1 (en) 2004-01-07
US20040248898A1 (en) 2004-12-09
EP2044958A3 (en) 2009-07-08
PT1378246E (pt) 2009-05-22
ES2324766T3 (es) 2009-08-14

Similar Documents

Publication Publication Date Title
CN1553814B (zh) 用于治疗动脉硬化的药物组合物
JP5764555B2 (ja) 治療組成物および関連する使用方法
Sinatra et al. Solid-phase synthesis of cereblon-recruiting selective histone deacetylase 6 degraders (HDAC6 PROTACs) with antileukemic activity
JP6333280B2 (ja) グルタミナーゼ阻害剤およびその使用方法
JP5756457B2 (ja) ピルビン酸キナーゼｍ２調節剤、治療組成物および関連する使用方法
CN102040550B (zh) 胞质磷脂酶a2抑制剂
Aitdafoun et al. 4-Alkoxybenzamidines as new potent phospholipase A2 inhibitors
WO2018148443A1 (en) Tunable endogenous protein degradation with heterobifunctional compounds
EA020045B1 (ru) Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах
JP2009514893A (ja) 多価インドール化合物およびホスホリパーゼａ２インヒビターとしてのその使用
JPH10502624A (ja) Ｐｌａ▲下２▼インヒビターおよび腸管コレステロール吸収の阻害のためのその使用
Hines et al. Allosteric inhibition of the neuropeptidase neurolysin
JP2009515837A (ja) Ｃ４−酸性置換基を有するインドール化合物およびホスホリパーゼａ２インヒビターとしてのその使用
JP2009514892A (ja) 多価ホスホリパーゼインヒビターを含むホスホリパーゼインヒビター、および内腔に局在化されるホスホリパーゼインヒビターとしての使用を含むその使用
CN106231900A (zh) 化合物及其使用方法
CN113543852A (zh) 吡咯并吡唑衍生物
Tong et al. Dimethyl sulfoxide-free and water-soluble fluorescent probe for detection of bovine serum albumin prepared by ionic Co-assembly of amphiphiles
Daines et al. (E)-3-[6-[[(2, 6-dichlorophenyl) thio] methyl]-3-(2-phenylethoxy)-2-pyridinyl]-2-propenoic acid: A high-affinity leukotriene B4 receptor antagonist with oral antiinflammatory activity
Yang et al. Multipathway regulation induced by 4‐(phenylsulfonyl) morpholine derivatives against triple‐negative breast cancer
JP2009514883A (ja) アザインドール化合物およびホスホリパーゼａ２インヒビターとしてのその使用
Imberg et al. Pyrazinyl-Substituted Aminoazoles as Covalent Inhibitors of Thrombin: Synthesis, Structure, and Anticoagulant Properties
Moineaux et al. Synthesis, crystal structures and electronic properties of isomers of chloro-pyridinylvinyl-1H-indoles
US20110118173A1 (en) Method of delipidation of hdl using serum opacity factor to prevent, inhibit, and/or reverse atherosclerosis
Sieders Activity-& Affinity-Based Phospholipase Profiling: The Design, Synthesis and Biological Evaluation of Phospholipase-Targeting Activity-and Affinity-Based Probes and Inhibitors
O'Connell Design and synthesis of inhibitors of endothelial lipase, a new target for raising HDL

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100526

Termination date: 20130319